|
1.
|
|
19 p, 1.6 MB |
Strategies to design clinical studies to identify predictive biomarkers in cancer research
/
Perez-Gracia, Jose Luis (Clínica Universidad de Navarra) ;
Sanmamed, Miguel F. (Yale University School of Medicine) ;
Bosch, Ana (Lund University) ;
Patiño-Garcia, Ana (Clínica Universidad de Navarra) ;
Schalper, Kurt A. (Yale School of Medicine) ;
Segura, Victor (Universidad de Navarra) ;
Bellmunt, Joaquim (Dana-Farber Cancer Institute and Harvard Medical School) ;
Tabernero, Josep (Hospital Universitari Vall d'Hebron) ;
Sweeney, Christopher J. (Dana-Farber Cancer Institute and Harvard Medical School) ;
Choueiri, Toni K. (Dana-Farber Cancer Institute and Harvard Medical School) ;
Martín Jiménez, Miguel (Hospital Gregorio Marañón. Instituto de Investigación Sanitaria) ;
Fusco, Juan Pablo (Clínica Universidad de Navarra) ;
Rodriguez-Ruiz, Maria Esperanza (Universidad de Navarra) ;
Calvo, Alfonso (Universidad de Navarra) ;
Prior, Celia (Universidad de Navarra) ;
Paz-Ares, Luis (Hospital Universitario 12 de Octubre (Madrid)) ;
Pio, Ruben (Universidad de Navarra) ;
Gonzalez-Billalabeitia, Enrique (Universidad Católica San Antonio de Murcia) ;
Gonzalez Hernandez, Alvaro (Clínica Universidad de Navarra) ;
Páez, David (Institut d'Investigació Biomèdica Sant Pau) ;
Piulats, Jose María (Institut Català d'Oncologia) ;
Gurpide, Alfonso (Universidad de Navarra) ;
Andueza, Mapi (Clínica Universidad de Navarra) ;
de Velasco, Guillermo (Dana-Farber Cancer Institute and Harvard Medical School) ;
Pazo, Roberto (Hospital Universitario Miguel Servet (Saragossa)) ;
Grande, Enrique (Hospital Universitario Ramón y Cajal (Madrid)) ;
Nicolas, Pilar (Universidad del País Vasco) ;
Abad-Santos, Francisco (Instituto de Investigación Sanitaria la Princesa (IP)) ;
Garcia-Donas, Jesus (Centro Integral Oncológico HM Clara Campal) ;
Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ;
Pajares, María J. (Universidad de Navarra) ;
Suárez, Cristina (Hospital Universitari Vall d'Hebron) ;
Colomer, Ramon (Hospital Universitario de la Princesa (Madrid)) ;
Montuenga, Luis M. (Universidad de Navarra) ;
Melero, Ignacio (Universidad de Navarra) ;
Universitat Autònoma de Barcelona
The discovery of reliable biomarkers to predict efficacy and toxicity of anticancer drugs remains one of the key challenges in cancer research. Despite its relevance, no efficient study designs to identify promising candidate biomarkers have been established. [...]
2017 -  10.1016/j.ctrv.2016.12.005
Cancer Treatment Reviews, Vol. 53 (january 2017) , p. 79-97
|
|
|
2.
|
|
13 p, 792.3 KB |
SEOM clinical guideline thyroid cancer (2019)
/
Gallardo, Enrique (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Medina, J. (Hospital Virgen de la Salud (Toledo)) ;
Sánchez, J.C. (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Viúdez, A. (Complejo Hospitalario de Navarra) ;
Grande, E. (MD Anderson Cancer Center) ;
Porras, I. (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ;
Ramon y Cajal, Teresa (Institut d'Investigació Biomèdica Sant Pau) ;
Trigo, J. (Hospital Universitario Regional Virgen de la Victoria) ;
Iglesias, L. (Hospital 12 de Octubre (Madrid)) ;
Capdevila, J. (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Thyroid carcinoma is the most frequent endocrine malignancy and accounts for around 3% of global cancer incidence. Different histologies and clinical scenarios make necessary a multidisciplinary approach that includes new diagnostic methods and surgical, radiopharmaceutical and systemic therapies. [...]
2020 - 10.1007/s12094-019-02284-8
Clinical & Translational Oncology, Vol. 22 Núm. 2 (january 2020) , p. 223-235
|
|
|
3.
|
|
10 p, 1.6 MB |
Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy : results of an international multicentre registry
/
Gimeno, Juan R. (Center for Biomedical Network Research on Cardiovascular Diseases (CIBERCV)) ;
Olivotto, Iacopo (Careggi University Hospital (Florència, Itàlia)) ;
Rodríguez, Ana Isabel (European Reference Networks for rare, low prevalence and complex diseases of the heart (ERN GUARD-Heart)) ;
Ho, Carolyn Y. (Brigham and Women's Hospital (Boston, Estats Units d'Amèrica)) ;
Fernández, Adrián (Favaloro Foundation University Hospital) ;
Quiroga, Alejandro (Favaloro Foundation University Hospital) ;
Espinosa, Mari Angeles (Hospital General Universitario Gregorio Marañón) ;
Gómez-González, Cristina (Hospital General Universitario Gregorio Marañón) ;
Robledo, María (Hospital Universitario Araba (Txagorritxu)) ;
Tojal-Sierra, Lucas (Hospital Universitario Araba (Txagorritxu)) ;
Day, Sharlene M. (Hospital of the University of Pennsylvania) ;
Owens, Anjali (Hospital of the University of Pennsylvania) ;
Barriales-Villa, Roberto (Complejo Hospitalario Universitario de A Coruña) ;
Larrañaga, Jose María (Complejo Hospitalario Universitario de A Coruña) ;
Rodriguez-Palomares, Jose F (Hospital Universitari Vall d'Hebron) ;
González-del-Hoyo, Maribel (Hospital Universitari Vall d'Hebron) ;
Piqueras-Flores, Jesús (Hospital General Universitario de Ciudad Real) ;
Reza, Nosheen (Hospital of the University of Pennsylvania) ;
Chumakova, Olga (Municipal Clinical Hospital #17) ;
Ashley, Euan A. (Stanford University Medical Center) ;
Parikh, Victoria (Stanford University Medical Center) ;
Wheeler, Matthew (Stanford University Medical Center) ;
Jacoby, Daniel (Yale New Haven Hospital) ;
Pereira, Alexandre C. (Hospital das Clinicas da Univerisidade de Sao Paulo) ;
Saberi, Sara (University of Michigan Hospital) ;
Helms, Adam S. (University of Michigan Hospital) ;
Villacorta, Eduardo (Universidad de Salamanca) ;
Gallego-Delgado, María (Universidad de Salamanca) ;
de Castro, Daniel (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Domınguez, Fernando (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Ripoll-Vera, Tomás (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Zorio, Esther (Hospital Universitari i Politècnic La Fe (València)) ;
Sánchez-Martínez, José Carlos (Hospital Universitari i Politècnic La Fe (València)) ;
García-Álvarez, Ana (Hospital Clínic i Provincial de Barcelona) ;
Arbelo, Elena (Hospital Clínic i Provincial de Barcelona) ;
Mogollón, María Victoria (Hospital San Pedro de Alcántara) ;
Fuentes-Cañamero, María Eugenia (Badajoz University Hospital) ;
Grande, Elias (Dilemma Solution S.L) ;
Peña, Carlos (Dilemma Solution S.L) ;
Monserrat, Lorenzo (Dilemma Solution S.L) ;
Lakdawala, Neal K. (Brigham and Women's Hospital (Boston, Estats Units d'Amèrica)) ;
Universitat Autònoma de Barcelona
To describe the natural history of SARS-CoV-2 infection in patients with hypertrophic cardiomyopathy (HCM) compared with a control group and to identify predictors of adverse events. Three hundred and five patients [age 56. [...]
2022 - 10.1002/ehf2.13964
ESC Heart Failure, Vol. 9 (june 2022) , p. 2189-2198
|
|
|
4.
|
|
9 p, 1.2 MB |
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide
/
Fernandez-Perez, María P. (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Perez-Navarro, Enrique (Hospital Universitario 12 de Octubre (Madrid)) ;
Alonso-Gordoa, Teresa (Hospital Universitario Ramón y Cajal (Madrid)) ;
Conteduca, Vincenza (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) "Dino Amadori" IRCCS) ;
Font, Albert (Institut Català d'Oncologia) ;
Vázquez-Estévez, Sergio (H. Universitario Lucus Augusti) ;
González-del-Alba, Aránzazu (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Wetterskog, Daniel (Paul O'Gorman Building) ;
Antonarakis, Emmanuel S. (Johns Hopkins University School of Medicine) ;
Mellado, Begona (Hospital Clínic i Provincial de Barcelona) ;
Fernandez-Calvo, Ovidio (Complejo Hospitalario Universitario Ourense) ;
Méndez-Vidal, María J. (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Climent, Miguel Ángel (Fundació Institut Valencià d'Oncologia) ;
Duran, Ignacio (Instituto de Biomedicina de Sevilla) ;
Gallardo, Enrique (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Rodriguez Sanchez, Angel (Hospital Universitario de León) ;
Santander, Carmen (Hospital Universitario Miguel Servet (Saragossa)) ;
Sáez, Maria I. (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Puente, Javier (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos) ;
Tudela, Julian (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Martínez, Alberto (Biobanco de la región de Murcia) ;
López-Andreo, Maria J. (SAI-IMIB-Universidad de Murcia) ;
Padilla, José (Hospital Universitario Morales Meseguer) ;
Lozano, Rebeca (Instituto de Investigación Biomédica de Málaga) ;
Hervas, David (Instituto de Investigación Sanitaria La Fe) ;
Luo, Jun (Johns Hopkins University School of Medicine) ;
De Giorgi, Ugo (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) "Dino Amadori" IRCCS) ;
Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ;
Attard, Gerhardt (Paul O'Gorman Building) ;
Grande, Enrique (MD Anderson Cancer Center Madrid) ;
Gonzalez-Billalabeitia, Enrique (Universidad Católica San Antonio de Murcia-UCAM) ;
Universitat Autònoma de Barcelona
There is a considerable need to incorporate biomarkers of resistance to new antiandrogen agents in the management of castration-resistant prostate cancer (CRPC). We conducted a phase II trial of enzalutamide in first-line chemo-naïve asymptomatic or minimally symptomatic mCRPC and analyzed the prognostic value of TMPRSS2-ERG and other biomarkers, including circulating tumor cells (CTCs), androgen receptor splice variant (AR-V7) in CTCs and plasma Androgen Receptor copy number gain (AR-gain). [...]
2022 - 10.1002/pros.24469
The Prostate, Vol. 83 (december 2022)
|
|
|
5.
|
|
16 p, 2.1 MB |
Recent therapeutic advances in urothelial carcinoma : A paradigm shift in disease management
/
Bellmunt, J. (Department of Medical Oncology. Beth Israel Deaconess Medical Center and IMIM-PSMAR Lab. Harvard Medical School) ;
Valderrama, B.P. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Puente, J. (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos) ;
Grande, Enrique (MD Anderson Cancer Center Madrid) ;
Bolós, M.V. (Pfizer) ;
Laínez, Nuria (Hospital Universitario de Navarra) ;
Vázquez, S. (Hospital Universitario Lucus Augusti (Lugo)) ;
Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau) ;
Climent, Miguel Ángel (Department of Medical Oncology. Valencia Institute of Oncology Foundation) ;
Garcia del Muro, Xavier (Institut d'Investigació Biomèdica de Bellvitge) ;
Arranz, J.Á. (Hospital General Universitario Gregorio Marañón) ;
Durán, Ignacio (Instituto de Investigación Sanitaria Valdecilla (Santander, Cantàbria)) ;
Universitat Autònoma de Barcelona
Management of first-line advanced urothelial carcinoma (UC) has consisted during the past three decades in the administration of platinum-based chemotherapy followed by observation. Despite moderate to high response rates to first-line treatment, most patients will relapse shortly after and the outcomes with subsequent therapies are poor with 5-year overall survival rates of 5% in the pre-immunotherapy era. [...]
2022 - 10.1016/j.critrevonc.2022.103683
Critical Reviews in Oncology/Hematology, Vol. 174 (june 2022) , p. 103683
|
|
|
6.
|
|
7 p, 549.5 KB |
Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
/
Powles, Thomas (University of London. Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust, Queen Mary) ;
Motzer, Robert J. (Memorial Sloan Kettering Cancer Center) ;
Escudier, Bernard (Gustave Roussy) ;
Pal, Sumanta (City of Hope National Medical Center) ;
Kollmannsberger, Christian (BCCA Vancouver Cancer Centre. British Columbia Cancer Agency) ;
Pikiel, Joanna (Wojewodzkie Centrum Onkologii, 80-219 Gdańsk, Poland) ;
Gurney, Howard (Macquarie University. Macquarie University and Westmead Hospital) ;
Rha, Sun Young (Yonsei Cancer Center. Severance Hospital) ;
Park, Se Hoon (Samsung Medical Center) ;
Geertsen, Poul F. (Copenhagen University Hospital) ;
Gross-Goupil, Marine (Groupe Hospitalier Saint André, 33000 Bordeaux, France) ;
Grande, Enrique (Hospital Universitario Ramón y Cajal (Madrid)) ;
Suárez, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Markby, David W. (Exelixis, Inc) ;
Arroyo, Alan (Exelixis, Inc) ;
Dean, Mark (Exelixis, Inc) ;
Choueiri, Toni K. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
George, Daniel (Duke University Medical Center) ;
Universitat Autònoma de Barcelona
In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS), objective response rate (ORR), and overall survival (OS) versus everolimus in patients with advanced renal cell carcinoma (RCC), after prior antiangiogenic therapy. [...]
2018 - 10.1038/s41416-018-0164-0
British Journal of Cancer, Vol. 119 (september 2018) , p. 663-669
|
|
|
7.
|
|
8 p, 518.2 KB |
Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib : comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)
/
Solis-Hernandez, Mª Pilar (Hospital Universitario Central de Asturias) ;
Fernandez del Valle, Ana (Hospital Universitario Central de Asturias) ;
Carmona-Bayonas, Alberto (Hospital General Universitario Morales Meseguer (Múrcia)) ;
García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ;
Custodio, Ana (Hospital Universitario La Paz (Madrid)) ;
Benavent, Marta (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Alonso-Gordoa, Teresa (Hospital Universitario Ramón y Cajal (Madrid)) ;
Nuñez-Valdovino, Bárbara (Hospital Clinico Universidad de Chile (Santiago de Xile, Xile)) ;
Sanchez Canovas, Manuel (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Matos, Ignacio (Hospital Universitari Vall d'Hebron) ;
Alonso, Vicente (Hospital Universitario Miguel Servet (Saragossa)) ;
Lopez, Carlos (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Viudez, Antonio (Complejo Hospitalario de Navarra) ;
Izquierdo, Marta (Hospital Universitario Central de Asturias) ;
Calvo-Temprano, David (Hospital Universitario Central de Asturias) ;
Grande, Enrique (MD Anderson Cancer Center) ;
Capdevila Castillón, Jaume (Hospital Universitari Vall d'Hebron) ;
Jimenez-Fonseca, Paula (Hospital Universitario Central de Asturias) ;
Universitat Autònoma de Barcelona ;
Vall d'Hebron Institut d'Oncologia
The purpose of our study was to analyse the usefulness of Choi criteria versus RECIST in patients with pancreatic neuroendocrine tumours (PanNETs) treated with sunitinib. A multicentre, prospective study was conducted in 10 Spanish centres. [...]
2019 - 10.1038/s41416-019-0558-7
British Journal of Cancer, Vol. 121 (september 2019) , p. 537-544
|
|
|
8.
|
|
11 p, 939.2 KB |
Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog : The GETNE-TRASGU Study
/
Carmona-Bayonas, Alberto (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Jiménez-Fonseca, Paula (Hospital Universitario Central de Asturias) ;
Lamarca, Ángela (The Christie NHS Foundation Trust, Manchester) ;
Barriuso, Jorge (University of Manchester) ;
Castaño, Ángel (Hospital Universitario de Fuenlabrada ( Madrid)) ;
Benavent, Marta (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Alonso, Vicente (Hospital Universitario Miguel Servet (Saragossa)) ;
Riesco-Martínez, María del Carmen (Hospital Universitario 12 de Octubre (Madrid)) ;
Alonso-Gordoa, Teresa (Hospital Universitario Ramón y Cajal (Madrid)) ;
Custodio, Ana (Hospital Universitario La Paz (Madrid)) ;
Sánchez Cánovas, Manuel (Instituto Murciano de Investigación Biosanitaria) ;
Hernando Cubero, Jorge (Vall d'Hebron Institut d'Oncologia) ;
López, Carlos (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Lacasta, Adelaida (Hospital Universitario de Donostia (Sant Sebastià, País Basc)) ;
Fernández Montes, Ana (Complejo Hospitalario Universitario de Ourense) ;
Marazuela, Mónica (Hospital Universitario de la Princesa (Madrid)) ;
Crespo, Guillermo (Complejo Asistencial Universitario de Burgos) ;
Escudero, Pilar (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Diaz, José Ángel (Hospital Clínico San Carlos (Madrid)) ;
Feliciangeli, Eduardo (Hospital General Universitario Santa Lucía (Cartagena, Múrcia)) ;
Gallego, Javier (Hospital General Universitario de Elche) ;
Llanos, Marta (Hospital Universitario de Canarias (La Laguna)) ;
Segura, Ángel (Hospital Universitari i Politècnic La Fe (València)) ;
Vilardell, Felip (Hospital Arnau de Vilanova (Lleida, Catalunya)) ;
Percovich, Juan Carlos (Hospital General Universitario Gregorio Marañón) ;
Grande, Enrique (MD Anderson Cancer Center Madrid) ;
Capdevila Castillón, Jaume (Hospital Universitari Vall d'Hebron) ;
Valle, Juan W. (University of Manchester, Manchester) ;
García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ;
Universitat Autònoma de Barcelona
Somatostatin analogs (SSAs) are recommended for the first-line treatment of most patients with well-differentiated, gastroenteropancreatic (GEP) neuroendocrine tumors; however, benefit from treatment is heterogeneous. [...]
2019 - 10.1200/JCO.19.00980
Journal of Clinical Oncology, Vol. 37 (august 2019) , p. 2571-2580
|
|
|
9.
|
|
12 p, 182.8 KB |
Economics of gastroenteropancreatic neuroendocrine tumors : a systematic review
/
Grande, Enrique (Hospital Universitario Ramón y Cajal (Madrid)) ;
Díaz, Ángel (Hospital Clínico San Carlos (Madrid)) ;
López, Carlos (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Munarriz, Javier (Consorci Hospitalari Provincial de Castelló) ;
Reina, Juan-José (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ;
Vera, Ruth (Complejo Hospitalario de Navarra) ;
Bernárdez, Beatriz (Complejo Hospitalario Universitario de Santiago de Compostela) ;
Aller, Javier (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Capdevila Castillón, Jaume (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
García-Carbonero, Rocío ;
Jimenez Fonseca, Paula ;
Trapero-Bertran, Marta (Universitat Internacional de Catalunya) ;
Universitat Autònoma de Barcelona
Despite current interest, enthusiasm and progress in the development of therapies for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs), there are substantial gaps in the published literature regarding cost-of-illness analyses, economic evaluation and budget impact analyses. [...]
2019 - 10.1177/2042018819828217
Therapeutic Advances in Endocrinology and Metabolism, Vol. 10 (february 2019)
|
|
|
10.
|
|
12 p, 2.4 MB |
Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib
/
Jiménez-Fonseca, Paula (Medical Oncology Department, Hospital Universitario Central de Asturias) ;
Martín, Miguel Navarro (Instituto de Investigación Biomédica de Salamanca) ;
Carmona-Bayonas, Alberto (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Calvo, Alfonso (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ;
Fernández-Mateos, Javier (Complejo Asistencial Universitario de Salamanca. Instituto de Investigación Biomédica de Salamanca) ;
Redrado, Miriam (IDISNA and Program in Solid Tumors and Biomarkers, Center for Applied Medical Research (CIMA), Department of Histology and Pathology, University of Navarra, Pamplona) ;
Capdevila Castillón, Jaume (Hospital Universitari Vall d'Hebron) ;
Lago, Nieves Martínez (Complejo Hospitalario Universitario de A Coruña) ;
Lacasta, Adelaida (Hospital Universitario de Donostia (Sant Sebastià, País Basc)) ;
Muñarriz, Javier (Consorci Hospitalari Provincial de Castelló) ;
Segura, Ángel (Hospital Universitari i Politècnic La Fe (València)) ;
Fuster, Josep (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Barón, Francisco (Complejo Hospitalario Universitario de Santiago de Compostela) ;
Llanos, Marta (Hospital Universitario de Canarias (La Laguna)) ;
Serrano, Raquel (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Castillo, Alfredo (Hospital Universitario Central de Asturias) ;
Cruz Hernández, Juan Jesús (Instituto de Investigación Biomédica de Salamanca) ;
Grande, Enrique (Medical Oncology Department, MD Anderson Cancer Center) ;
Universitat Autònoma de Barcelona
Several circulating biomarkers and single nucleotide polymorphisms (SNPs) have been correlated with efficacy and tolerability to antiangiogenic agents. These associations remain unexplored in well-differentiated, metastatic pancreatic neuroendocrine tumors treated with the multitargeted tyrosine kinase inhibitor sunitinib. [...]
2018 - 10.18632/oncotarget.26380
Oncotarget, Vol. 9 (december 2018) , p. 36894-36905
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
